Abstract
The “smoker’s paradox”, where smokers have improved survival post-myocardial infarction, was predominantly observed in the thrombolytic era. However, evidence for the smoker’s paradox in the current era of PCI therapy is both limited and inconsistent. We aimed to examine the effect of smoking status on survival in unselected ST-elevation myocardial infarction (STEMI) patients managed by primary percutaneous coronary intervention (PCI). Data were collected for all patients with acute STEMI undergoing primary PCI at The South Yorkshire Cardiothoracic Centre, UK over a 5-year period between 2009 and 2014. Differences in survival by smoking status were assessed before and after adjustment for differences in baseline variables using a Kaplan–Meier curve and a Cox regression analysis, respectively. A total of 3133 STEMI patients were included in the study. After adjustment for differences in baseline variables, smoking was associated with a significantly increased mortality (hazard ratio 1.35 (95% CI 1.04–1.74)) compared to never smokers after 3 years. The risk for ex-smokers (hazard ratio 0.99 (0.76–1.28)) was similar to never smokers. There were no significant differences in survival by smoking status at 30 days and 1 year. In this large registry of STEMI patients managed by primary PCI, smokers had a significantly higher 3-year mortality than non-smokers. This study is the first to not only dispel the existence of the smoker’s paradox, but to highlight a high-risk subgroup who may warrant tailored secondary prevention treatment, including smoking cessation.
Similar content being viewed by others
Abbreviations
- DANAMI-2:
-
Second Danish Multicenter Trial in Acute Myocardial Infarction
- NHS REC:
-
National Health Service Research Ethics Committee
- ONS:
-
Office for National Statistics
References
Yusuf S et al (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364(9438):937–952
Steele L et al (2015) A retrospective cross-sectional study on the association between tobacco smoking and incidence of ST-segment elevation myocardial infarction and cardiovascular risk factors. Postgrad Med J 91(1079):492–496
Grines CL et al (1995) Effect of cigarette smoking on outcome after thrombolytic therapy for myocardial infarction. Circulation 91(2):298–303
Gottlieb S et al (1996) Smoking and prognosis after acute myocardial infarction in the thrombolytic era (Israeli Thrombolytic National Survey). J Am Coll Cardiol 28(6):1506–1513
Jorgensen et al (1999) The prognostic importance of smoking status at the time of acute myocardial infarction in 6676 patients. TRACE Study Group. J Cardiovasc Risk 6(1):23–27
Kelly TL et al (1985) Smoking status at the time of acute myocardial infarction and subsequent prognosis. Am Heart J 110(3):535–541
Molstad P (1991) First myocardial infarction in smokers. Eur Heart J 12(7):753–759
Barbash GI et al (1995) Evaluation of paradoxic beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: mechanism of the “smoker’s paradox”; from the GUSTO-I trial, with angiographic insights. Global utilization of streptokinase and tissue-plasminogen activator for occluded coronary arteries. J Am Coll Cardiol 26(5):1222–1229
Gourlay SG, Rundle AC, Barron HV (2002) Smoking and mortality following acute myocardial infarction: results from the National Registry of Myocardial Infarction 2 (NRMI 2). Nicotine Tob Res 4(1):101–107
Venkatason P et al (2016) The bizzare phenomenon of smokers’ paradox in the immediate outcome post acute myocardial infarction: an insight into the Malaysian National Cardiovascular Database-Acute Coronary Syndrome (NCVD-ACS) registry year 2006–2013. SpringerPlus 5:534
Chen KY et al (2012) ‘Smoker’s paradox’ in young patients with acute myocardial infarction. Clin Exp Pharmacol Physiol 39(7):630–635
Desai NR et al (2009) Interaction between cigarette smoking and clinical benefit of clopidogrel. J Am Coll Cardiol 53(15):1273–1278
Cornel JH et al (2014) Impact of smoking status on platelet function and clinical outcomes with prasugrel vs. clopidogrel in patients with acute coronary syndromes managed without revascularization: insights from the TRILOGY ACS trial. Am Heart J 168(1):76–87 e1
Kim YG et al (2016) Cigarette smoking does not enhance clopidogrel responsiveness after adjusting verifynow P2Y12 reaction unit for the influence of hemoglobin level. JACC Cardiovasc Interv 9(16):1680–1690
Aune E et al (2011) The “smoker’s paradox” in patients with acute coronary syndrome: a systematic review. BMC Med 9:97
Steele L et al (2017) A retrospective cohort study of the association between smoking and mortality after acute ST-segment elevation myocardial infarction. Postgrad Med J 93(1102):489–493
Gupta T et al (2016) Smoker’s paradox in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. J Am Heart Assoc 5(4):e003370
Arbel Y et al (2014) Temporal trends in all-cause mortality of smokers versus non-smokers hospitalized with ST-segment elevation myocardial infarction. Int J Cardiol 176(1):171–176
Migration Yorkshire (2013) South Yorkshire local migration profile. http://www.migrationyorkshire.org.uk/userfiles/attachments/pages/634/southyorkshirelmpsummary-nov2013.pdf. Accessed 26 Feb 2014
Rasmussen T et al (2012) Smokers with ST-segment elevation myocardial infarction and short time to treatment have equal effects of PCI and fibrinolysis. J Invasive Cardiol 24(8):401–406
Sherif MA et al (2011) Impact of smoking on the outcome of patients treated with drug-eluting stents: 1-year results from the prospective multicentre German Drug-Eluting Stent Registry (DES.DE). Clin Res Cardiol 100(5):413–423
Weisz G et al (2005) Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction—the smoker’s paradox revisited. Am Heart J 150(2):358–364
Rakowski T et al (2012) Impact of smoking status on outcome in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. J Thromb Thrombolysis 34(3):397–403
Goto K et al (2011) Impact of smoking on outcomes of patients with ST-segment elevation myocardial infarction (from the HORIZONS-AMI Trial). Am J Cardiol 108(10):1387–1394
Kodaira M et al (2016) Effect of smoking status on clinical outcome and efficacy of clopidogrel in acute coronary syndrome. Circ J 80(7):1590–1599
Mohamedali B, Shroff A (2013) Impact of smoking status on cardiovascular outcomes following percutaneous coronary intervention. Clin Cardiol 36(7):372–377
Allahwala UK et al (2013) Absence of a ‘smoker’s paradox’ in field triaged ST-elevation myocardial infarction patients undergoing percutaneous coronary intervention. Cardiovasc Revasc Med 14(4):213–217
Reinstadler SJ et al (2017) Association of smoking with myocardial injury and clinical outcome in patients undergoing mechanical reperfusion for ST-elevation myocardial infarction. Eur Heart J Cardiovasc Imaging 18(1):39–45
Gennaro G et al (2016) Effect of smoking on infarct size and major adverse cardiac events in patients with large anterior ST-elevation myocardial infarction (from the INFUSE-AMI Trial). Am J Cardiol 118(8):1097–1104
Lloyd A et al (2017) Pronounced increase in risk of acute ST-segment elevation myocardial infarction in younger smokers. Heart 103(8):586–591
Krosnick JA et al (2017) Perceptions of health risks of cigarette smoking: a new measure reveals widespread misunderstanding. PLoS ONE 12(8):e0182063
Pagidipati NJ et al (2017) Use of prescription smoking cessation medications after myocardial infarction among older patients in community practice. JAMA Cardiol 2(9):1040–1042
Robertson JO et al (2014) Impact of cigarette smoking on extent of coronary artery disease and prognosis of patients with non-ST-segment elevation acute coronary syndromes: an analysis from the ACUITY Trial (Acute Catheterization and Urgent Intervention Triage Strategy). JACC Cardiovasc Interv 7(4):372–379
Zhang Y et al (2015) Smoking is associated with adverse clinical outcomes in patients undergoing revascularization with PCI or CABG: the SYNTAX trial at 5-year follow-up. J Am Coll Cardiol 65(11):1107–1115
Acknowledgements
We thank Dr. Dawn Teare for providing statistical advice.
Funding
This study received no specific funding, and was carried out as a University of Sheffield degree project.
Author information
Authors and Affiliations
Contributions
All authors were involved in the preparation of the manuscript, have read the manuscript, agree with the analyses of the data and the conclusions reached in the manuscript, and are accountable for all aspects of the work.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no competing interests.
Rights and permissions
About this article
Cite this article
Steele, L., Palmer, J., Lloyd, A. et al. The impact of smoking on mortality after acute ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: a retrospective cohort outcome study at 3 years. J Thromb Thrombolysis 47, 520–526 (2019). https://doi.org/10.1007/s11239-019-01812-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11239-019-01812-1